<div id="readability-page-1"><p>Renaissance Technologies LLC raised its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 7.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,462,459 shares of the company's stock after buying an additional 103,859 shares during the quarter. Renaissance Technologies LLC owned 0.22% of Genmab A/S worth $36,752,000 at the end of the most recent quarter.</p><p>A number of other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new stake in shares of Genmab A/S during the fourth quarter valued at approximately $393,000. Principal Securities Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter worth $77,000. PNC Financial Services Group Inc. grew its holdings in shares of Genmab A/S by 5.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 165,187 shares of the company's stock valued at $5,260,000 after buying an additional 8,463 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Genmab A/S during the fourth quarter valued at $4,875,000. Finally, Assetmark Inc. raised its position in Genmab A/S by 6.4% during the fourth quarter. Assetmark Inc. now owns 43,518 shares of the company's stock valued at $1,386,000 after buying an additional 2,636 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors. </p><h2>Genmab A/S Trading Down 0.9 %</h2><p>GMAB stock opened at $26.20 on Thursday. The firm has a market cap of $17.33 billion, a PE ratio of 21.83, a PEG ratio of 0.81 and a beta of 0.99. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $37.97. The company has a fifty day simple moving average of $27.29 and a 200 day simple moving average of $28.02. </p><p>Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, analysts forecast that Genmab A/S will post 1.27 EPS for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have weighed in on GMAB shares. BTIG Research lifted their target price on Genmab A/S from $46.00 to $47.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, June 27th. Royal Bank of Canada raised shares of Genmab A/S from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating in a research report on Monday, July 15th. Morgan Stanley reiterated an &#34;equal weight&#34; rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial lowered their price target on shares of Genmab A/S from $53.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, September 9th. Finally, JPMorgan Chase &amp; Co. reiterated a &#34;neutral&#34; rating on shares of Genmab A/S in a report on Tuesday, August 20th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $45.20.</p><p><b>View Our Latest Report on GMAB</b></p><h2>About Genmab A/S</h2> (Free Report)<p>Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Genmab A/S</li><li>How Can Investors Benefit From After-Hours Trading</li><li>How Much Can You Make in Stocks in One Month?</li><li>What Do S&amp;P 500 Stocks Tell Investors About the Market? </li><li>This Is the Top Large-Cap Stock Insiders Are Buying</li><li>How to Most Effectively Use the MarketBeat Earnings Screener</li><li>Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R01BQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R01BQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ China Stockpiling Gold “Like No Tomorrow” <span><span>(From True Gold Republic)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTk0"/></p><h2>Should you invest $1,000 in Genmab A/S right now?</h2><p>Before you consider Genmab A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.</p><p>While Genmab A/S currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

GMAB

<p>Renaissance Technologies LLC increased its stake in Genmab A/S (NASDAQ:GMAB) by 7.6% in Q2, owning 1,462,459 shares after acquiring an additional 103,859 shares. Other hedge funds also adjusted their positions in Genmab. The stock is currently trading down 0.9%, with a market cap of $8.33 billion and a PE ratio of 21.83. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average price target of $25.20. Genmab develops antibody therapeutics for cancer treatment, including DARZALEX and teprotumumab.</p>

Genmab A/S (NASDAQ:GMAB) Stake Boosted by Renaissance Technologies LLC